Product Name
IFT80, siRNA
Full Product Name
IFT80 siRNA (Human)
Product Synonym Names
KIAA1374; WDR56; Intraflagellar transport protein 80 homolog; WD repeat-containing protein 56
Product Gene Name
IFT80 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q9P2H3
Specificity
IFT80 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human IFT80 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of IFT80 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
IFT80 sirna
siRNA to inhibit IFT80 expression using RNA interference
Applications Tested/Suitable for IFT80 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for IFT80. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001177170.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001190241.1
[Other Products]
UniProt Primary Accession #
Q9P2H3
[Other Products]
UniProt Secondary Accession #
Q3MJC4; Q86YF4; Q9UIX1; B4E0K1; C9J8I0[Other Products]
UniProt Related Accession #
Q9P2H3[Other Products]
Molecular Weight
123,321 Da
NCBI Official Full Name
intraflagellar transport protein 80 homolog isoform b
NCBI Official Synonym Full Names
intraflagellar transport 80
NCBI Official Symbol
IFT80??[Similar Products]
NCBI Official Synonym Symbols
ATD2; SRTD2; WDR56
??[Similar Products]
NCBI Protein Information
intraflagellar transport protein 80 homolog
UniProt Protein Name
Intraflagellar transport protein 80 homolog
UniProt Synonym Protein Names
WD repeat-containing protein 56
Protein Family
Intraflagellar transport protein
UniProt Gene Name
IFT80??[Similar Products]
UniProt Synonym Gene Names
KIAA1374; WDR56??[Similar Products]
UniProt Entry Name
IFT80_HUMAN
NCBI Summary for IFT80
The protein encoded by this gene is part of the intraflagellar transport complex B and is necessary for the function of motile and sensory cilia. Defects in this gene are a cause of asphyxiating thoracic dystrophy 2 (ATD2). Three transcript variants encoding two different isoforms have been found for this gene.[provided by RefSeq, Jun 2010]
UniProt Comments for IFT80
IFT80: Component of the intraflagellar transport (IFT) complex B, which is essential for the development and maintenance of motile and sensory cilia. Defects in IFT80 are the cause of asphyxiating thoracic dystrophy type 2 (ATD2). An autosomal recessive chondrodysplasia characterized by a severely constricted thoracic cage, short-limbed short stature, and polydactyly. It often leads to death in infancy because of respiratory insufficiency. Retinal degeneration, cystic renal disease and hepatic disease can be present in affected individuals who survive early childhood.
Chromosomal Location of Human Ortholog: 3q25.33
Cellular Component: centrosome; cytoplasm; cilium
Biological Process: osteoblast differentiation; smoothened signaling pathway; organelle organization and biogenesis; chondrocyte differentiation; positive regulation of smoothened signaling pathway; cilium biogenesis; negative regulation of epithelial cell proliferation
Disease: Short-rib Thoracic Dysplasia 2 With Or Without Polydactyly
Research Articles on IFT80
1. Mutations in IFT80 can be responsible for a lethal form of short-rib polydactyly and provide the molecular basis for the Jeune-Verma-Naumoff dysplasia spectrum.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
